• Anderson, J.A., Archin, N.M., Ince, W., Parker, D., Wiegand, A., Coffin, J.M., Kuruc, J., Eron, J., Swanstrom, R.,Margolis, D.M., 2011. Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J Virol, 85, 5220-5223.

  • Banerjee, A., Li, L., Pirrone, V., Krebs, F.C., Wigdahl, B.,Nonnemacher, M.R., 2017. cAMP Signaling Enhances HIV-1 Long Terminal Repeat (LTR)-directed Transcription and Viral Replication in Bone Marrow Progenitor Cells. Clin Med Insights Pathol, 10, 1179555717694535.

  • Barbian, H.J., Seaton, M.S., Narasipura, S.D., Wallace, J., Rajan, R., Sha, B.E.,Al-Harthi, L., 2022. beta-catenin regulates HIV latency and modulates HIV reactivation. PLoS Pathog, 18, e1010354.

  • Bosque, A.,Planelles, V., 2009. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood, 113, 58-65.

  • Brenchley, J.M., Price, D.A., Schacker, T.W., Asher, T.E., Silvestri, G., Rao, S., Kazzaz, Z., Bornstein, E., Lambotte, O., Altmann, D., Blazar, B.R., Rodriguez, B., Teixeira-Johnson, L., Landay, A., Martin, J.N., Hecht, F.M., Picker, L.J., Lederman, M.M., Deeks, S.G.,Douek, D.C., 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med, 12, 1365-1371.

  • Browne, E.P., 2020. The Role of Toll-Like Receptors in Retroviral Infection. Microorganisms, 8.

  • Casazza, J.P., Brenchley, J.M., Hill, B.J., Ayana, R., Ambrozak, D., Roederer, M., Douek, D.C., Betts, M.R.,Koup, R.A., 2009. Autocrine production of beta-chemokines protects CMV-Specific CD4 T cells from HIV infection. PLoS Pathog, 5, e1000646.

  • Caselli, E., Benedetti, S., Gentili, V., Grigolato, J.,Di Luca, D., 2012. Short communication:activating transcription factor 4 (ATF4) promotes HIV type 1 activation. AIDS Res Hum Retroviruses, 28, 907-912.

  • Chinese Medical Association, Chinese Center for Disease Control and Prevention. 2021. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2021 edition). Zhonghua Nei Ke Za Zhi, 60, 1106-1128.

  • Claireaux, M., Robinot, R., Kervevan, J., Patgaonkar, M., Staropoli, I., Brelot, A., Nouel, A., Gellenoncourt, S., Tang, X., Hery, M., Volant, S., Perthame, E., Avettand-Fenoel, V., Buchrieser, J., Cokelaer, T., Bouchier, C., Ma, L., Boufassa, F., Hendou, S., Libri, V., Hasan, M., Zucman, D., De Truchis, P., Schwartz, O., Lambotte, O.,Chakrabarti, L.A., 2022. Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry. Nat Commun, 13, 521.

  • Clerici, M.,Shearer, G.M., 1993. A TH1——>TH2 switch is a critical step in the etiology of HIV infection. Immunol Today, 14, 107-111.

  • Crespo-Bermejo, C., De Arellano, E.R., Lara-Aguilar, V., Valle-Millares, D., Gomez-Lus, M.L., Madrid, R., Martin-Carbonero, L.,Briz, V., 2021. Persistent low-Level viremia in persons living with HIV undertreatment:An unresolved status. Virulence, 12, 2919-2931.

  • Doitsh, G., Cavrois, M., Lassen, K.G., Zepeda, O., Yang, Z., Santiago, M.L., Hebbeler, A.M.,Greene, W.C., 2010. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell, 143, 789-801.

  • Doitsh, G., Galloway, N.L., Geng, X., Yang, Z., Monroe, K.M., Zepeda, O., Hunt, P.W., Hatano, H., Sowinski, S., Munoz-Arias, I.,Greene, W.C., 2014. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature, 505, 509-514.

  • Dutilleul, A., Rodari, A.,Van Lint, C., 2020. Depicting HIV-1 Transcriptional Mechanisms:A Summary of What We Know. Viruses, 12.

  • Eisenberg, S.P., Evans, R.J., Arend, W.P., Verderber, E., Brewer, M.T., Hannum, C.H.,Thompson, R.C., 1990. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature, 343, 341-346.

  • Giri, J.G., Wells, J., Dower, S.K., Mccall, C.E., Guzman, R.N., Slack, J., Bird, T.A., Shanebeck, K., Grabstein, K.H., Sims, J.E.,Et Al., 1994. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol, 153, 5802-5809.

  • Goffin, V., Demonte, D., Vanhulle, C., De Walque, S., De Launoit, Y., Burny, A., Collette, Y.,Van Lint, C., 2005. Transcription factor binding sites in the pol gene intragenic regulatory region of HIV-1 are important for virus infectivity. Nucleic Acids Res, 33, 4285-4310.

  • Gonzalez-Serna, A., Swenson, L.C., Watson, B., Zhang, W., Nohpal, A., Auyeung, K., Montaner, J.S.,Harrigan, P.R., 2016. A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure. Clin Microbiol Infect, 22, 1004 e1009-1004 e1016.

  • Hannum, C.H., Wilcox, C.J., Arend, W.P., Joslin, F.G., Dripps, D.J., Heimdal, P.L., Armes, L.G., Sommer, A., Eisenberg, S.P.,Thompson, R.C., 1990. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature, 343, 336-340.

  • Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H.,Bauer, S., 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science, 303, 1526-1529.

  • Henderson, A., Holloway, A., Reeves, R.,Tremethick, D.J., 2004. Recruitment of SWI/SNF to the human immunodeficiency virus type 1 promoter. Mol Cell Biol, 24, 389-397.

  • Henrick, B.M., Yao, X.D., Rosenthal, K.L.,Team, I.S., 2015. HIV-1 Structural Proteins Serve as PAMPs for TLR2 Heterodimers Significantly Increasing Infection and Innate Immune Activation. Front Immunol, 6, 426.

  • Hermans, L.E., Moorhouse, M., Carmona, S., Grobbee, D.E., Hofstra, L.M., Richman, D.D., Tempelman, H.A., Venter, W.D.F.,Wensing, A.M.J., 2018. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes:a multicentre cohort study. Lancet Infect Dis, 18, 188-197.

  • Heufler, C., Koch, F., Stanzl, U., Topar, G., Wysocka, M., Trinchieri, G., Enk, A., Steinman, R.M., Romani, N.,Schuler, G., 1996. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol, 26, 659-668.

  • Kang, J.Y., Nan, X., Jin, M.S., Youn, S.J., Ryu, Y.H., Mah, S., Han, S.H., Lee, H., Paik, S.G.,Lee, J.O., 2009. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity, 31, 873-884.

  • Kolakowska, A., Maresca, A.F., Collins, I.J.,Cailhol, J., 2019. Update on Adverse Effects of HIV Integrase Inhibitors. Curr Treat Options Infect Dis, 11, 372-387.

  • Konstantopoulos, C., Ribaudo, H., Ragland, K., Bangsberg, D.R.,Li, J.Z., 2015. Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia. Open Forum Infect Dis, 2, ofu119.

  • Liang, Z., Xu, J.,Gu, C., 2020. Novel role of the SRY-related high-mobility-group box D gene in cancer. Semin Cancer Biol, 67, 83-90.

  • Liu, X., Wang, Y., Lu, H., Li, J., Yan, X., Xiao, M., Hao, J., Alekseev, A., Khong, H., Chen, T., Huang, R., Wu, J., Zhao, Q., Wu, Q., Xu, S., Wang, X., Jin, W., Yu, S., Wang, Y., Wei, L., Wang, A., Zhong, B., Ni, L., Liu, X., Nurieva, R., Ye, L., Tian, Q., Bian, X.W.,Dong, C., 2019. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. Nature, 567, 525-529.

  • Ma, S., Wan, X., Deng, Z., Shi, L., Hao, C., Zhou, Z., Zhou, C., Fang, Y., Liu, J., Yang, J., Chen, X., Li, T., Zang, A., Yin, S., Li, B., Plumas, J., Chaperot, L., Zhang, X., Xu, G., Jiang, L., Shen, N., Xiong, S., Gao, X., Zhang, Y.,Xiao, H., 2017. Epigenetic regulator CXXC5 recruits DNA demethylase Tet2 to regulate TLR7/9-elicited IFN response in pDCs. J Exp Med, 214, 1471-1491.

  • Macedo, A.B., Novis, C.L.,Bosque, A., 2019. Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists. Front Immunol, 10, 2450.

  • Maekawa, Y., Tsukumo, S., Chiba, S., Hirai, H., Hayashi, Y., Okada, H., Kishihara, K.,Yasutomo, K., 2003. Delta1-Notch3 interactions bias the functional differentiation of activated CD4+ T cells. Immunity, 19, 549-559.

  • Martinez, V., Costagliola, D., Bonduelle, O., N'go, N., Schnuriger, A., Théodorou, I., Clauvel, J.P., Sicard, D., Agut, H., Debré, P., Rouzioux, C.,Autran, B., 2005. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis, 191, 2053-2063.

  • Mclaren, P.J., Gawanbacht, A., Pyndiah, N., Krapp, C., Hotter, D., Kluge, S.F., Gotz, N., Heilmann, J., Mack, K., Sauter, D., Thompson, D., Perreaud, J., Rausell, A., Munoz, M., Ciuffi, A., Kirchhoff, F.,Telenti, A., 2015. Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses. Retrovirology, 12, 41.

  • Meas, H.Z., Haug, M., Beckwith, M.S., Louet, C., Ryan, L., Hu, Z., Landskron, J., Nordbo, S.A., Tasken, K., Yin, H., Damas, J.K.,Flo, T.H., 2020. Sensing of HIV-1 by TLR8 activates human T cells and reverses latency. Nat Commun, 11, 147.

  • Nickel, K., Halfpenny, N.J.A., Snedecor, S.J.,Punekar, Y.S., 2021. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naive patients infected with HIV-1:an update on a systematic review and network meta-analysis. BMC Infect Dis, 21, 222.

  • Palich, R., Wirden, M., Peytavin, G., Le, M.P., Seang, S., Abdi, B., Schneider, L., Tubiana, R., Valantin, M.A., Paccoud, O., Soulie, C., Calvez, V., Katlama, C.,Marcelin, A.G., 2020. Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations. J Antimicrob Chemother, 75, 2981-2985.

  • Pasquereau, S., Kumar, A.,Herbein, G., 2017. Targeting TNF and TNF Receptor Pathway in HIV-1 Infection:from Immune Activation to Viral Reservoirs. Viruses, 9.

  • Pei, X.H., Lv, X.Q.,Li, H.X., 2014. Sox5 induces epithelial to mesenchymal transition by transactivation of Twist1. Biochem Biophys Res Commun, 446, 322-327.

  • Poltorak, A., He, X., Smirnova, I., Liu, M.Y., Van Huffel, C., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., Freudenberg, M., Ricciardi-Castagnoli, P., Layton, B.,Beutler, B., 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice:mutations in Tlr4 gene. Science, 282, 2085-2088.

  • Presky, D.H., Yang, H., Minetti, L.J., Chua, A.O., Nabavi, N., Wu, C.Y., Gately, M.K.,Gubler, U., 1996. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A, 93, 14002-14007.

  • Rabbi, M.F., Saifuddin, M., Gu, D.S., Kagnoff, M.F.,Roebuck, K.A., 1997. U5 region of the human immunodeficiency virus type 1 long terminal repeat contains TRE-like cAMP-responsive elements that bind both AP-1 and CREB/ATF proteins. Virology, 233, 235-245.

  • Rasquinha, M.T., Sur, M., Lasrado, N.,Reddy, J., 2021. IL-10 as a Th2 Cytokine:Differences Between Mice and Humans. J Immunol, 207, 2205-2215.

  • Reus, S., Portilla, J., Sánchez-Payá, J., Giner, L., Francés, R., Such, J., Boix, V., Merino, E.,Gimeno, A., 2013. Low-level HIV viremia is associated with microbial translocation and inflammation. J Acquir Immune Defic Syndr, 62, 129-134.

  • Rubbo, P.A., Tuaillon, E., Bollore, K., Foulongne, V., Bourdin, A., Nagot, N., Van De Perre, P., Desgranges, C., Israel-Biet, D.,Vendrell, J.P., 2011. The potential impact of CD4+ T cell activation and enhanced Th1/Th2 cytokine ratio on HIV-1 secretion in the lungs of individuals with advanced AIDS and active pulmonary infection. Clin Immunol, 139, 142-154.

  • Sun, C., Ban, Y., Wang, K., Sun, Y.,Zhao, Z., 2019. SOX5 promotes breast cancer proliferation and invasion by transactivation of EZH2. Oncol Lett, 17, 2754-2762.

  • Swenson, L.C., Min, J.E., Woods, C.K., Cai, E., Li, J.Z., Montaner, J.S., Harrigan, P.R.,Gonzalez-Serna, A., 2014. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS, 28, 1125-1134.

  • Szabo, S.J., Kim, S.T., Costa, G.L., Zhang, X., Fathman, C.G.,Glimcher, L.H., 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell, 100, 655-669.

  • Tobin, N.H., Learn, G.H., Holte, S.E., Wang, Y., Melvin, A.J., Mckernan, J.L., Pawluk, D.M., Mohan, K.M., Lewis, P.F., Mullins, J.I.,Frenkel, L.M., 2005. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes:expression of archival virus and replication of virus. J Virol, 79, 9625-9634.

  • Torres, B., Rallon, N.I., Lonca, M., Diaz, A., Alos, L., Martinez, E., Cruceta, A., Arnaiz, J.A., Leal, L., Lucero, C., Leon, A., Sanchez, M., Negredo, E., Clotet, B., Gatell, J.M., Benito, J.M.,Garcia, F., 2014. Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients:a randomized clinical trial. AIDS Res Hum Retroviruses, 30, 425-433.

  • Tsuchiya, Y., Naito, T., Tenno, M., Maruyama, M., Koseki, H., Taniuchi, I.,Naoe, Y., 2016. ThPOK represses CXXC5, which induces methylation of histone H3 lysine 9 in Cd40lg promoter by association with SUV39H1:implications in repression of CD40L expression in CD8+ cytotoxic T cells. J Leukoc Biol, 100, 327-338.

  • Van Den Eeckhout, B., Tavernier, J.,Gerlo, S., 2020. Interleukin-1 as Innate Mediator of T Cell Immunity. Front Immunol, 11, 621931.

  • Viglianti, G.A., Planelles, V.,Hanley, T.M., 2021. Interactions with Commensal and Pathogenic Bacteria Induce HIV-1 Latency in Macrophages through Altered Transcription Factor Recruitment to the LTR. J Virol, 10.1128/JVI.02141-20.

  • World Health Organization, 2016. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection:Recommendations for a Public Health Approach. Geneva.

  • Xiong, X., Tu, S., Wang, J., Luo, S.,Yan, X., 2019. CXXC5:A novel regulator and coordinator of TGF-beta, BMP and Wnt signaling. J Cell Mol Med, 23, 740-749.

  • Yang, R., Mele, F., Worley, L., Langlais, D., Rosain, J., Benhsaien, I., Elarabi, H., Croft, C.A., Doisne, J.M., Zhang, P., Weisshaar, M., Jarrossay, D., Latorre, D., Shen, Y., Han, J., Ogishi, M., Gruber, C., Markle, J., Al Ali, F., Rahman, M., Khan, T., Seeleuthner, Y., Kerner, G., Husquin, L.T., Maclsaac, J.L., Jeljeli, M., Errami, A., Ailal, F., Kobor, M.S., Oleaga-Quintas, C., Roynard, M., Bourgey, M., El Baghdadi, J., Boisson-Dupuis, S., Puel, A., Batteux, F., Rozenberg, F., Marr, N., Pan-Hammarstrom, Q., Bogunovic, D., Quintana-Murci, L., Carroll, T., Ma, C.S., Abel, L., Bousfiha, A., Di Santo, J.P., Glimcher, L.H., Gros, P., Tangye, S.G., Sallusto, F., Bustamante, J.,Casanova, J.L., 2020. Human T-bet Governs Innate and Innate-like Adaptive IFN-gamma Immunity against Mycobacteria. Cell, 183, 1826-1847 e1831.

  • Yang, X., Chen, Y.,Gabuzda, D., 1999. ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappaB. J Biol Chem, 274, 27981-27988.

  • Yeung, M.L., Houzet, L., Yedavalli, V.S.,Jeang, K.T., 2009. A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication. J Biol Chem, 284, 19463-19473.

  • Younas, M., Psomas, C., Reynes, C., Cezar, R., Kundura, L., Portales, P., Merle, C., Atoui, N., Fernandez, C., Le Moing, V., Barbuat, C., Sotto, A., Sabatier, R., Winter, A., Fabbro, P., Vincent, T., Reynes, J.,Corbeau, P., 2021. Residual Viremia Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults Under Efficient Antiretroviral Therapy. Front Immunol, 12, 663843.

  • Yu, H., Kim, P.M., Sprecher, E., Trifonov, V.,Gerstein, M., 2007. The importance of bottlenecks in protein networks:correlation with gene essentiality and expression dynamics. PLoS Comput Biol, 3, e59.

  • Zhu, C., Sakuishi, K., Xiao, S., Sun, Z., Zaghouani, S., Gu, G., Wang, C., Tan, D.J., Wu, C., Rangachari, M., Pertel, T., Jin, H.T., Ahmed, R., Anderson, A.C.,Kuchroo, V.K., 2015. An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat Commun, 6, 6072.